Obesity pharmacology: Past, present, and future

Current Opinion in Gastroenterology

Volumn 18, Issue 2, 2002, Pages 213-220

  Kushner, Robert F ^a   Manzano, Hazel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CILIARY NEUROTROPHIC FACTOR; DEXFEN; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; PHENYLPROPANOLAMINE; PLACEBO; PSYLLIUM HYDROCOLLOID; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT LEPTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG;

BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENERGY CONSUMPTION; FOOD INTAKE; GASTROINTESTINAL DISEASE; GENETIC ANALYSIS; HEART DISEASE; HEMORRHAGIC SHOCK; HUMAN; INJECTION SITE; MOLECULAR BIOLOGY; OBESITY; PREVALENCE; REVIEW; RISK ASSESSMENT; SKIN MANIFESTATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; WEIGHT REDUCTION;

EID: 0036204890     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200203000-00011     Document Type: Review

References (87)

1. Current and potential drugs for treatment of obesity
2. Pharmacological treatment of obesity: Therapeutic strategies
3. A concise review on the therapeutics of obesity
4. Pharmacotherapy for obesity
5. Drug treatment of obesity: From past failures to future successes?
6. Long-term pharmacotherapy of obesity 2000: A review of efficacy and safety
7. Medicinal strategies in the treatment of obesity
8. Valvular heart disease associated with fenfluramine-phentermine
9. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations
10. ACC/AHA guidelines for the management of patients with valvular heart disease: Executive summary
11. The fen-phen finale: A study of weight loss and valvular disease
12. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs
13. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
14. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
15. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication
16. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
17. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine
18. Low prevalence of valvular disease in 226 phentermin-fenfluramine protocol subjects prospectively followed for up to 30 MONTHS
19. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine
20. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine
21. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
22. Diet drug-related cardiac valve disease: The Mayo Clinic echocardiographic laboratory experience
23. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities
24. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease
25. Echocardiographic examination of women previously treated with fenfluramine
26. Phenylpropanolamine and the risk of hemorrhagic stroke
27. Effects of sibutramine on resting metabolic rate and weight loss in overweight women
28. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
29. Sibutramine produces dose-related weight loss
30. Long-term weight loss with sibutramine
31. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial
32. Effect of sibutramine on weight maintenance after weight loss: A randomized trial
33. Weight loss with sibutramine improves glycaemic control and other metabolic parameters on obese patients with type 2 diabetes mellitus
34. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo-controlled study
35. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients
36. Absence of cardiac valve dysfunction in obese patients treated with sibutramine
37. Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet-exercise intervention
38. Second phase of a double-blind study clinical trial on sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over
39. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial
40. Orlistat: A novel weight loss therapy
41. Retrospective population-based analysis of the dose-response (fecal fat excretion) relation of orlistat in normal and obese volunteers
42. A one-year trial to assess the value of orlistat in the management of obesity
43. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
44. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized trial
45. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1 -year study
46. Orlistat in the long-term treatment of obesity in primary care settings
47. One-year treatment of obesity: A randomized double-blind, placebo-controlled, multicenter study of orlistat, a gastrointestinal lipase inhibitor
48. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
49. Early weight loss with orlistat predicts 18-month weight reduction
50. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
51. Orlistat inhibits dietary cholesterol absorption
52. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid)
53. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men
54. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight
55. Model for the regulation of energy balance and adiposity by the central nervous system
56. Adiposity signals and the control of energy homeostasis
57. Genetics of body weight regulation
58. Human genomics and obesity: Finding appropriate drug targets
59. Food intake and the regulation of body weight
60. Bupropion: A review of its mechanism of antidepressant activity
61. Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women
62. Influence of topiramate in the regulation of energy balance
63. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: Alterations in hormones, neuropeptide, and uncoupling-protein mRNAs
64. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats
65. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
66. Axokine causes significant weight loss in severely and morbidly obese subjects
67. Positional cloning of the mouse obese gene and its human homologue
68. Congenital leptin deficiency is associated with severe early-onset obesity in humans
69. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
70. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial
71. Significant body composition changes observed in obese subjects receiving chronic subcutaneous administration of a modified form of recombinant human leptin
72. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men
73. The future of leptin analogues in the treatment of obesity
74. Neuropeptides and obesity
75. Central nervous system control of food intake
76. Obesity and the hypothalamus: Novel peptides for new pathways
77. Novel anti-obesity drugs
78. A typical Y1 receptor regulates feeding behaviors: Effects of a potent and selective Y1 antagonist, J-115814
79. Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin signaling in rats
80. Melanocortin receptor agonists improve glucose tolerance and obesity in obese mice
81. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity
82. Circumventing leptin resistance for weight control
83. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
84. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors
85. Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting